Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24426129 | 0.79 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CCR3NPC1LMNA | |
| SCHEMBL29622892 | 0.77 | TRPV1 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL29622860 | 0.76 | TRPV1 (0.62) | ALDH1A1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL6811739 | 0.68 | SMN1; SMN2 (0.71) | ALDH1A1NPC1LMNAHTTMEN1 | |
| SCHEMBL363351 | 0.68 | NPC1 (0.60) | ALDH1A1MCHR1CCR3NPC1LMNA | |
| SCHEMBL16828026 | 0.67 | KMT2A (0.79) | L3MBTL1MCHR1CCR3SIGMAR1MEN1 | |
| SCHEMBL2043178 | 0.67 | MEN1 (0.61) | ALDH1A1NPC1LMNAHTTMEN1 | |
| SCHEMBL8208996 | 0.67 | LMNA (0.62) | MCHR1NPC1LMNAHTTMEN1 | |
| SCHEMBL4981504 | 0.66 | KMT2A (0.74) | ALDH1A1L3MBTL1MCHR1MEN1KMT2A | |
| SCHEMBL8843511 | 0.66 | DPP7 (0.59) | ALDH1A1NPC1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3307742-B1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2016201266-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | ALDH1A1 4128/4885L3MBTL1 807/4885MCHR1 4267/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | ALDH1A1 442/4885L3MBTL1 3209/4885MCHR1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.